Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Bladder Cancer, December 2024

Free Subscription


Abstracts

Retrieve all available abstracts of the following 265 articles:
HTML format


 

Single Articles

  1. XU Z, Wu Y, Bai Y, Chen X, et al
    Identification of tumor-antigen signatures and immune subtypes for mRNA vaccine selection in muscle-invasive bladder cancer.
    Surgery. 2024 Nov 28:108926. doi: 10.1016/j.surg.2024.
    PubMed    
    Abstract available

  2. ZHOU J, Zhang L, Wu H, Gao SL, et al
    Ferroptosis-related lncRNA AL136084.3 is associated with NUPR1 in bladder cancer.
    Discov Oncol. 2024;15:730.
    PubMed    
    Abstract available

  3. RASHAD AH, Abdel Hady HH, Assem A, Mohamed ME, et al
    Identification of Molecular Subgroups of Muscle-Invasive Urothelial Bladder Cancer and Their Impact on Treatment Outcome.
    Asian Pac J Cancer Prev. 2024;25:3953-3965.
    PubMed    
    Abstract available

  4. RAZMI M, Saeednejad Zanjani L, Rahimi M, Sajed R, et al
    Nuclear Expression of Dynamin 2 Is Associated With Tumor Aggressiveness in Bladder Cancer Patients: A Bioinformatics and Experimental Approach.
    Cancer Rep (Hoboken). 2024;7:e2133.
    PubMed    
    Abstract available

  5. BASHARAT S, Sajjad A, Javaid F, Khan M, et al
    EVALUATION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXPRESSION IN UROTHELIAL CARCINOMA: A POSSIBLE PROGNOSTIC ROLE.
    J Ayub Med Coll Abbottabad. 2024;36:274-278.
    PubMed    
    Abstract available

  6. DENG D, Xiao J, Liu J, Li H, et al
    Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.
    J Hematol Oncol. 2024;17:117.
    PubMed    
    Abstract available

  7. KEUM C, Yeom H, Noh TI, Yi SY, et al
    Diagnosis of early-stage bladder cancer via unprocessed urine samples at the point of care.
    Nat Biomed Eng. 2024 Nov 28. doi: 10.1038/s41551-024-01298.
    PubMed    
    Abstract available

  8. LI Z, Li J, Cao Q, Shen T, et al
    Transcription factor TCF7L1 targeting HSPB6 is involved in EMT and PI3K/AKT/mTOR pathways in bladder cancer.
    J Biol Chem. 2024 Nov 26:108024. doi: 10.1016/j.jbc.2024.108024.
    PubMed    
    Abstract available

  9. JEONG MS, Baek SW, Yang GE, Mun JY, et al
    Chemoresistance-Motility Signature of Molecular Evolution to Chemotherapy in Non-Muscle-Invasive Bladder Cancer and Its Clinical Implications.
    Cancer Lett. 2024 Nov 26:217339. doi: 10.1016/j.canlet.2024.217339.
    PubMed    
    Abstract available

  10. MA Y, Sun Y, Guo H, Yang R, et al
    Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies.
    Front Immunol. 2024;15:1418131.
    PubMed    
    Abstract available

  11. LI X, Qian B, Chen X, Shen M, et al
    The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.
    Front Immunol. 2024;15:1464327.
    PubMed    
    Abstract available

  12. WU L, Zhu K, Sun Y, Li T, et al
    Nucleolar protein 3 promotes proliferation of bladder cancer cells through the PI3K-Akt pathway.
    World J Surg Oncol. 2024;22:316.
    PubMed    
    Abstract available

  13. YAN X, Li Q, Xiao S, Chen J, et al
    Sulfasalazine-loaded nanoframes: A new frontier in bladder cancer therapy through ferroptosis induction.
    Colloids Surf B Biointerfaces. 2024;246:114394.
    PubMed    
    Abstract available

  14. BAO Q, Li Y, Chen Y, Zheng J, et al
    Transcriptome-Based Network Analysis Related to Histone Deacetylase Genes and Identified EMP1 as a Potential Biomarker for Prognosis in Bladder Cancer.
    Clin Genitourin Cancer. 2024;23:102262.
    PubMed    
    Abstract available

  15. GOFRIT ON, Goldberg SN, Lorber A, Duvdevani M, et al
    Quantifying treatment burden: the patient burden score a study of 758 patients across three clinical urologic scenarios.
    World J Urol. 2024;42:650.
    PubMed    
    Abstract available

  16. LIU LY, Tian L, Gao LH, Cui HJ, et al
    E2F8 facilitates malignant phenotypes of muscle-invasive bladder cancer via increasing MCM7 expression.
    Biochem Cell Biol. 2024 Nov 27. doi: 10.1139/bcb-2024-0083.
    PubMed    
    Abstract available

  17. SHARMA A, Raghavendra RT, Biswal D, Yadav P, et al
    Rationale of restaging transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer in the current era.
    Urol Ann. 2024;16:288-291.
    PubMed    
    Abstract available

  18. MASSARO M, Ciani R, Grossi G, Cavallaro G, et al
    Halloysite Nanotube-Based Delivery of Pyrazolo[3,4-d]pyrimidine Derivatives for Prostate and Bladder Cancer Treatment.
    Pharmaceutics. 2024;16:1428.
    PubMed    
    Abstract available

  19. PIRAMIDE F, Sica M, Fondello G, Mesterca G, et al
    Use of Multiparametric and Biparametric Magnetic Resonance Imaging in Bladder Cancer Staging: Prospective Observational Study and Analysis of Radiologist Learning Curve.
    J Clin Med. 2024;13:6955.
    PubMed    
    Abstract available

  20. BESSA-GONCALVES M, Bras JP, Jesus TT, Prazeres H, et al
    TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR.
    Genes (Basel). 2024;15:1424.
    PubMed    
    Abstract available

  21. MITIUSHKINA NV, Tiurin VI, Anuskina AA, Bordovskaya NA, et al
    Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.
    Int J Mol Sci. 2024;25:12126.
    PubMed    
    Abstract available

  22. MLYNARCZYK G, Miklosz A, Chabowski A, Baranowski M, et al
    Urothelial Urinary Bladder Cancer Is Characterized by Stage-Dependent Aberrations in Metabolism of Bioactive Sphingolipids.
    Int J Mol Sci. 2024;25:11889.
    PubMed    
    Abstract available

  23. CROITOR A, Dema V, Latcu S, Bardan R, et al
    Clinical and Pathological Characteristics of Bladder Cancer in Patients Aged 18-45 Undergoing Transurethral Resection of Bladder Tumor.
    Biomedicines. 2024;12:2449.
    PubMed    
    Abstract available

  24. HASSOUNEH Z, Noel ODV, Ji N, Kim ME, et al
    Low-Dose Eribulin Promotes NK Cell-Mediated Therapeutic Efficacy in Bladder Cancer.
    Cancers (Basel). 2024;16:3875.
    PubMed    
    Abstract available

  25. CANO BARBADILLA T, Alvarez Perez M, Prieto Cuadra JD, Dawid de Vera MT, et al
    The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder Cancer.
    Diagnostics (Basel). 2024;14:2501.
    PubMed    
    Abstract available

  26. ABOU CHAKRA M, Packiam VT, McElree IM, Mott SL, et al
    The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancer.
    Urol Oncol. 2024 Nov 25:S1078-1439(24)00692.
    PubMed    
    Abstract available

  27. HE Y, Xiang L, Yuan J, Yan H, et al
    Lactylation Modification as a Promoter of Bladder Cancer: Insights from Multi-Omics Analysis.
    Curr Issues Mol Biol. 2024;46:12866-12885.
    PubMed    
    Abstract available

  28. TAYLOR J, Patel S, Gaitonde K, Greene K, et al
    The Management of Non-Muscle-Invasive Bladder Cancer in a Veteran Patient Population: Issues and Recommendations.
    Curr Oncol. 2024;31:6686-6698.
    PubMed    
    Abstract available

  29. LERNER SP, Tangen C, Svatek RS, Daneshmand S, et al
    Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
    N Engl J Med. 2024;391:1206-1216.
    PubMed    
    Abstract available

  30. SHI T, Yu D, Xu Y, Huang X, et al
    Analysis of postoperative complications in bladder cancer patients.
    Open Med (Wars). 2024;19:20241069.
    PubMed    
    Abstract available

  31. LU X, Ge LP, Liu Z, Zhu Y, et al
    CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer.
    Front Oncol. 2024;14:1498579.
    PubMed    
    Abstract available

  32. LI M, Varble NA, Gurram S, Long D, et al
    Bladder image stitching algorithm for navigation and referencing using a standard cystoscope.
    Sci Rep. 2024;14:29168.
    PubMed    
    Abstract available

  33. STEINER L, Eldh M, Offens A, Veerman RE, et al
    Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.
    Cancer Lett. 2024;609:217352.
    PubMed    
    Abstract available

  34. PORAV-HODADE D, Big SA, Barbos VI, Gherle B, et al
    Extraperitoneal Open Radical Cystectomy: A New Standard in Frail Patients with Muscle-Invasive Bladder Cancer?
    Clin Pract. 2024;14:2559-2567.
    PubMed    
    Abstract available

  35. SHAO Z, Wu G, Tang Y, Hou P, et al
    Aptamer-Gadolinium Conjugates for Targeted Magnetic Resonance Imaging of Early-Stage Bladder Cancer.
    Anal Chem. 2024 Nov 25. doi: 10.1021/acs.analchem.4c03659.
    PubMed    
    Abstract available

  36. GUO J, Zhang Y, He L, Wang X, et al
    Prognostic features of bladder cancer based on five neddylation-related genes.
    Am J Clin Exp Urol. 2024;12:240-254.
    PubMed    
    Abstract available

  37. DINH TJ, Rogg M, Cosenza-Contreras M, Li M, et al
    Proteomic analysis of non-muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment.
    J Pathol. 2024 Nov 25. doi: 10.1002/path.6367.
    PubMed    
    Abstract available

  38. WU X, Zhao Z, Yu W, Liu S, et al
    Single-Cell Multiomics Identifies Glycan Epitope LacNAc as a Potential Cell-Surface Effector Marker of Peripheral T Cells in Bladder Cancer Patients.
    ACS Chem Biol. 2024 Nov 24. doi: 10.1021/acschembio.4c00635.
    PubMed    
    Abstract available

  39. TASDEMIR MN, Eryuruk U, Oguz U, Tok B, et al
    The role of multiparametric magnetic resonance imaging in the differentiation of low- and high-grade non-muscle invasive bladder cancer.
    Diagn Interv Radiol. 2024 Nov 25. doi: 10.4274/dir.2024.243004.
    PubMed    
    Abstract available

  40. GAO W, Lou Z
    Single center evaluation of sensitivity and specificity of CellDetect assay in early bladder cancer patients.
    Sci Rep. 2024;14:29099.
    PubMed    
    Abstract available

  41. ISALI I, Almassi N, Nizam A, Campbell R, et al
    State of the Art: The Microbiome in Bladder Cancer.
    Urol Oncol. 2024 Nov 23:S1078-1439(24)00724.
    PubMed    
    Abstract available

  42. ROUMIGUIE M, Leon P, Xylinas E, Allory Y, et al
    French AFU Cancer Committee Guidelines - Update 2024-2026: Non-muscle invasive bladder cancer (NMIBC).
    Fr J Urol. 2024;34:102742.
    PubMed    
    Abstract available

  43. ROUMIGUIE M, Marcq G, Neuzillet Y, Bajeot AS, et al
    French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC).
    Fr J Urol. 2024;34:102741.
    PubMed    
    Abstract available

  44. SUARTZ CV, Fradet V, Toren P, Ribeiro-Filho LA, et al
    Reevaluating the Role of Extended Pelvic Lymphadenectomy in Muscle-Invasive Bladder Cancer: Insights From SWOG S1011 and LEA AB 25-02 Trials.
    Clin Genitourin Cancer. 2024;23:102249.
    PubMed    


  45. SONG DM, Feng K, Luo WF, Lv DS, et al
    Predicting survival in bladder cancer with a novel apoptotic gene-related prognostic model.
    Discov Oncol. 2024;15:702.
    PubMed    
    Abstract available

  46. LI D, Wu L, Qi L, Yu Q, et al
    Pseudouridine synthase 7 (PUS7) affects the prognosis and immune modulation of patients with bladder cancer.
    Asian J Surg. 2024 Nov 22:S1015-9584(24)02557.
    PubMed    


  47. BAUDELIN C, Sargos P, Dinart D, Hennequin C, et al
    Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials.
    Crit Rev Oncol Hematol. 2024;205:104557.
    PubMed    
    Abstract available

  48. ARIAFAR A, Mansourabadi Z, Alipoor H, Faghih Z, et al
    Gamma-delta T Cells in Bladder Cancer Draining Lymph Nodes.
    Iran J Immunol. 2024;21.
    PubMed    
    Abstract available

  49. YAN Y, Huang Z, Zhu Z, Wang Y, et al
    IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer.
    Cancer Cell Int. 2024;24:386.
    PubMed    
    Abstract available

  50. ZHANG J, Liu S, Wu M, Shi W, et al
    Clinical significance and expression of SLC35F6 in bladder urothelial carcinoma.
    Diagn Pathol. 2024;19:150.
    PubMed    
    Abstract available

  51. MATSUKAWA A, Yanagisawa T, Miszczyk M, Kardoust Parizi M, et al
    Trimodality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Matched Cohort Studies.
    Eur Urol Focus. 2024 Nov 21:S2405-4569(24)00244.
    PubMed    
    Abstract available

  52. BRASSART C, Coutte A, Wallet J, Meyer E, et al
    Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study.
    Cancer Radiother. 2024 Nov 21:S1278-3218(24)00169.
    PubMed    
    Abstract available

  53. TRIVEDI H, Kay H, Reines K, Hartzell J, et al
    Efficacy of Inpatient, Evidence-Based Tobacco Use Treatment of Patients With Bladder Cancer After Radical Cystectomy.
    Clin Genitourin Cancer. 2024;23:102252.
    PubMed    
    Abstract available

  54. YANG YX, Ye GC, Xiang JC, Luo KD, et al
    Differential Analysis of Surgical Treatment Modalities in T2N0M0 Bladder Cancer Patients: A Novel Propensity Score-Based Cohort Study.
    Clin Genitourin Cancer. 2024;23:102257.
    PubMed    
    Abstract available

  55. GUO C, Xiong X, Zhao X, Li Y, et al
    Superhydrophilic Fluorinated Polymer Probe for Zero-Background (19)F MRI with Adaptable Targeting Ability.
    ACS Appl Mater Interfaces. 2024;16:65319-65327.
    PubMed    
    Abstract available

  56. GRIVAS P, Barata P, Moon H, Gupta S, et al
    Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma: Results From the Real-World US PATRIOT-II Study.
    Clin Genitourin Cancer. 2024;22:102238.
    PubMed    
    Abstract available

  57. SEYEDIN SN, Harada GK, Garemanian E, Rafizadeh D, et al
    Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2024;22:102243.
    PubMed    
    Abstract available

  58. HARA T, Teishima J, Okamura Y, Suzuki K, et al
    Appearance of New Lesions Associate With Poor Prognosis in Pembrolizumab-Treated Urothelial Carcinoma.
    Clin Genitourin Cancer. 2024;22:102236.
    PubMed    
    Abstract available

  59. REIKE MJ, Raggi D, Mercinelli C, Cigliola A, et al
    Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study.
    Clin Genitourin Cancer. 2024;22:102214.
    PubMed    
    Abstract available

  60. MURALI A, Philips MR, Patidar S, Shree S, et al
    Total extra-peritoneal approach to radical cystectomy with ureterostomy: A novel technique for the elderly and frail.
    Urol Oncol. 2025;43:61.
    PubMed    
    Abstract available

  61. DAHMEN AS, Nusbaum DJ, Lazarovich A, Fialkoff J, et al
    Trends in the use of immediate postoperative intravesical chemotherapy following transurethral resection of bladder tumors.
    Urol Oncol. 2025;43:62.
    PubMed    
    Abstract available

  62. DE ANGELIS M, Jannello LMI, Siech C, Baudo A, et al
    Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma.
    Urol Oncol. 2025;43:62.
    PubMed    
    Abstract available

  63. LIVERINGHOUSE C, Sim AJ, Zhang J, Jain RK, et al
    A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2024;22:102222.
    PubMed    
    Abstract available

  64. STECCA C, Abdeljalil O, Sridhar SS
    Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study.
    Clin Genitourin Cancer. 2024;22:102215.
    PubMed    
    Abstract available

  65. COTILLAS EA, Bernardo C, Veerla S, Liedberg F, et al
    A Versatile and Upgraded Version of the LundTax Classification Algorithm Applied to Independent Cohorts.
    J Mol Diagn. 2024;26:1081-1101.
    PubMed    
    Abstract available

  66. SWEIS RF, Gajate P, Morales-Barrera R, Lee JL, et al
    Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.
    JAMA Oncol. 2024;10:1565-1570.
    PubMed    
    Abstract available

  67. GUILBERT A, Lebret T, Oudard S, Audenet F, et al
    Real-world evaluation of nivolumab utilization in adjuvant treatment of localized muscle-invasive urothelial carcinoma.
    Fr J Urol. 2024;34:102744.
    PubMed    
    Abstract available

  68. SUZUKI S, Gi M, Kobayashi T, Miyoshi N, et al
    Urinary bladder carcinogenic potential of 4,4'-methylenebis(2-chloroaniline) in humanized-liver mice.
    Toxicol Sci. 2024;202:210-219.
    PubMed    
    Abstract available

  69. ARTILES MEDINA A, Minguez Ojeda C, Subiela Henriquez JD, Muriel Garcia A, et al
    Nomograms to Appraise The Risk of Chronic Kidney Disease After Radical Cystectomy: Shifting The Focus to Prevention.
    Clin Genitourin Cancer. 2024;22:102205.
    PubMed    
    Abstract available

  70. BEN-DAVID R, Lidagoster S, Geduldig J, Kolanukuduru KP, et al
    The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysis.
    Urol Oncol. 2025;43:66.
    PubMed    
    Abstract available

  71. KOBAYASHI K, Matsumoto H, Sakano S, Yamamoto M, et al
    Comparative Efficacy of Avelumab Maintenance Therapy Versus Continued Chemotherapy Followed by Pembrolizumab in Metastatic Urothelial Carcinoma With No Progression After 4 Cycles of Chemotherapy: A Retrospective Study Using Propensity Score Matching.
    Clin Genitourin Cancer. 2024;22:102212.
    PubMed    
    Abstract available

  72. YU N, Xu C, Jiang Y, Liu D, et al
    Characteristics of Abdominal Fat Based on CT Measurements to Predict Early Recurrence After Initial Surgery of NMIBC in Stage Ta/T1.
    Clin Genitourin Cancer. 2024;22:102199.
    PubMed    
    Abstract available

  73. YASUDA Y, Numao N, Urasaki T, Oki R, et al
    Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution.
    Int J Clin Oncol. 2024;29:1925-1930.
    PubMed    
    Abstract available

  74. ZUO W, Zhang J, Xu L, Xiong G, et al
    Clinical, Prognosis, and Treatment Effect Features Analysis of Metachronous and Synchronous UTUC and BUC.
    Clin Genitourin Cancer. 2024;22:102192.
    PubMed    
    Abstract available

  75. ULLAH A, Lee KT, Chaudhury H, Yasinzai AQK, et al
    Prognostic Nomogram, Demographics and Comparative Analysis of Urinary Bladder Small Cell and Large Cell Neuroendocrine Carcinoma.
    Clin Genitourin Cancer. 2024;22:102183.
    PubMed    
    Abstract available

  76. MASUDA C, Onishi S, Yorozu K, Kurasawa M, et al
    PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model.
    Clin Exp Metastasis. 2024;41:909-924.
    PubMed    
    Abstract available

  77. ORSINI A, Bignante G, Lasorsa F, Bologna E, et al
    Urachal Carcinoma: Insights From a National Database.
    Clin Genitourin Cancer. 2024;22:102175.
    PubMed    
    Abstract available

  78. VECCIA A, Brusa D, Treccani L, Malandra S, et al
    Radical cystectomy with stentless urinary diversion: A systematic review and meta-analysis of comparative studies.
    Urol Oncol. 2025;43:54-60.
    PubMed    
    Abstract available

  79. KOLL FJ, Weers L, Weigert A, Banek S, et al
    Histopathologic, Molecular, and Clinical Profiling of Lymphoepithelioma-like Carcinoma of the Bladder.
    Mod Pathol. 2024;37:100588.
    PubMed    
    Abstract available

  80. ZENNAMI K, Sumitomo M, Nukaya T, Takenaka M, et al
    Impact of Urethra-Preserving Surgery During Radical Cystectomy: An Optimal Urethral Management in the Robotic Era.
    Clin Genitourin Cancer. 2024;22:102146.
    PubMed    
    Abstract available

  81. ABOU CHAAYA C, Ourfali S, Marchand C, Merienne C, et al
    Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC.
    Fr J Urol. 2024;34:102699.
    PubMed    
    Abstract available

  82. YANG GE, Kim MH, Jeong MS, Lee SY, et al
    Association between PDCD6-VNTR polymorphism and urinary cancer susceptibility.
    Genes Genomics. 2024;46:1281-1291.
    PubMed    
    Abstract available

  83. HERZBERG H, Babaoof R, Marom R, Veredgorn Y, et al
    Sterile Water Versus Glycine in Transurethral Resection of Bladder Tumors-Immunogenic and Clinical Implications.
    Eur Urol Focus. 2024;10:796-804.
    PubMed    
    Abstract available

  84. KHALATBARI F, Moafi-Madani M, Amin A
    Mixed-Grade Urothelial Carcinoma: Insights Into Clinical Behavior and Prognostic Implications Compared to Pure Low-Grade and High-Grade Urothelial Carcinomas.
    Arch Pathol Lab Med. 2024;148:1352-1357.
    PubMed    
    Abstract available

  85. CONTIERI R, Martini A, Mertens LS, Giannatempo P, et al
    The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma.
    Eur Urol Focus. 2024;10:662-665.
    PubMed    
    Abstract available

  86. HASSLER MR, Moedlagl V, Hindinger H, Krauter J, et al
    Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy.
    Eur Urol Focus. 2024;10:779-787.
    PubMed    
    Abstract available

  87. PALKOWSKI T, Bibeau F, Thiery-Vuillemin A, Kleinclauss F, et al
    High-Risk Non-Muscle Invasive Bladder Cancer: outcomes of patients who cannot benefit from Standard of Care.
    Fr J Urol. 2024 Dec 3:102838. doi: 10.1016/j.fjurol.2024.102838.
    PubMed    
    Abstract available

  88. TERZI E, Oz-Bedir BE, Ercan E, Ozdemir-Sanci T, et al
    beta-Arbutin and cisplatin: A combined approach to modulating apoptosis, cell viability, and migration in bladder cancer cells.
    Toxicol In Vitro. 2024 Dec 3:105985. doi: 10.1016/j.tiv.2024.105985.
    PubMed    
    Abstract available

  89. HU HY, Hu SY, Yang M, Hu Y, et al
    Hu similarity coefficient: a clinically oriented metric to evaluate contour accuracy in radiation therapy.
    Sci Rep. 2024;14:30215.
    PubMed    
    Abstract available

  90. SILVEIRA BM, Amparo TR, Seibert JB, Almeida TC, et al
    Hydromethanolic fraction from Abatia americana (Salicaceae) inhibits T24 bladder cancer cell line and the bacterium Listeria monocytogenes with high selectivity.
    Nat Prod Res. 2024 Dec 5:1-5. doi: 10.1080/14786419.2024.2435536.
    PubMed    
    Abstract available

  91. NISHIMURA Y, Oki Y, Nonomura D, Matsuzaki K, et al
    [A Case of Secondary Extramammary Paget's Disease Developed at 11 Years after Cystectomy].
    Hinyokika Kiyo. 2024;70:335-341.
    PubMed    
    Abstract available

  92. DE SOUSA NETO PI, Pinto VBP, Pianco EDS, Gomes ML, et al
    The role of microRNAs in non-invasive diagnosis of bladder cancer: a systematic review.
    Einstein (Sao Paulo). 2024;22:eRW0611.
    PubMed    
    Abstract available

  93. SADHUKHAN P, Feng M, Illingworth EJ, Sloma I, et al
    YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/ STAT3 pathway and CXCL deregulation.
    J Clin Invest. 2024 Nov 21:e171164. doi: 10.1172/JCI171164.
    PubMed    
    Abstract available

  94. CAO N, Cheng F, Zhou J, Liu N, et al
    Identification and construction of prognostic clusters and risk-prognosis model based on aging-immune related genes in bladder cancer.
    Discov Oncol. 2024;15:742.
    PubMed    
    Abstract available

  95. GABRIEL PE, Ganesan V, Krishnan J, Autorino R, et al
    Pure open versus robotic radical cystectomy with intracorporeal urinary diversion: a propensity matched analysis.
    World J Urol. 2024;43:13.
    PubMed    
    Abstract available

  96. ROMUNDSTAD L, Raeder J
    Does methadone offer any benefits for analgesia over morphine after bladder cancer surgery?
    Acta Anaesthesiol Scand. 2025;69:e14552.
    PubMed    


  97. YANG X, Zheng H, Huang J, Liu Y, et al
    Co-inhibition of PGF and VEGFA enhances the effectiveness of immunotherapy in bladder cancer.
    Int J Med Sci. 2024;21:2870-2882.
    PubMed    
    Abstract available

  98. ZOU J, Xu B, Luo P, Chen T, et al
    Non-coding RNAs in bladder cancer, a bridge between gut microbiota and host?
    Front Immunol. 2024;15:1482765.
    PubMed    
    Abstract available

  99. NARA T, Numakura K, Kikuchi A, Sekine Y, et al
    [Four Cases of Bladder Cancer in Young Patients with Severe Motor and Intellectual Disabilities].
    Hinyokika Kiyo. 2024;70:227-231.
    PubMed    
    Abstract available

  100. TUCCI FA, Pennisi R, Rigiracciolo DC, Filippone MG, et al
    Loss of NUMB drives aggressive bladder cancer via a RHOA/ROCK/YAP signaling axis.
    Nat Commun. 2024;15:10378.
    PubMed    
    Abstract available

  101. CRUPI E, Costa de Padua T, Marandino L, Fallara G, et al
    Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review.
    JCO Precis Oncol. 2024;8:e2400470.
    PubMed    
    Abstract available

  102. FERRO M, Tataru OS, Fallara G, Fiori C, et al
    Assessing the influence of smoking on inflammatory markers in bacillus Calmette Guerin response among bladder cancer patients: a novel machine-learning approach.
    Minerva Urol Nephrol. 2024 Dec 3. doi: 10.23736/S2724-6051.24.05876.
    PubMed    
    Abstract available

  103. DALL CP, Liu X, Faraj KS, Srivastava A, et al
    Hospital Quality and Racial Differences in Outcomes After Genitourinary Cancer Surgery.
    Cancer Med. 2024;13:e70436.
    PubMed    
    Abstract available

  104. YANG E, Ji L, Zhang X, Jing S, et al
    Identification of a Novel Mesenchymal Stem Cell-Related Signature for Predicting the Prognosis and Therapeutic Responses of Bladder Cancer.
    Stem Cells Int. 2024;2024:6064671.
    PubMed    
    Abstract available

  105. ZHANG Z, Liu F, Yu Y, Xie F, et al
    Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis.
    PeerJ. 2024;12:e18530.
    PubMed    
    Abstract available

  106. LI L, Guo Y, Wang C, Chang R, et al
    [High expression of miR-204-5p promotes malignant behaviors of bladder cancer cells by negatively regulating RAB22A].
    Nan Fang Yi Ke Da Xue Xue Bao. 2024;44:2235-2242.
    PubMed    
    Abstract available


  107. A two-phase point-of-care diagnostic device for bladder cancer.
    Nat Biomed Eng. 2024 Dec 2. doi: 10.1038/s41551-024-01301.
    PubMed    


  108. CAMPBELL T, Hunt TC, Li A, Cheng Z, et al
    Analysis of Genitourinary Rhabdomyosarcoma in Phase 3 clinical trials.
    World J Urol. 2024;43:6.
    PubMed    
    Abstract available


  109. RETRACTION: Upregulation of LncRNA SnoRNA Host Gene 6 Regulates NUAK Family SnF1-like Kinase-1 Expression by Competitively Binding MicroRNA-125b and Interacting with Snail1/2 in Bladder Cancer.
    J Cell Biochem. 2024 Dec 1:e30676. doi: 10.1002/jcb.30676.
    PubMed    
    Abstract available

  110. MALSHY K, Steidle M, Tabayoyong W, Messing EM, et al
    Letter to the Editor: Risk of Metachronous Upper Tract Urothelial Carcinoma After Ureteral Stenting in Patients With Bladder Cancer.
    Clin Genitourin Cancer. 2024;23:102263.
    PubMed    


  111. WU L, Yang E, Zhang Y, Yin B, et al
    An immune-related lncRNA signature for predicting overall survival and chemotherapy sensitivity in bladder cancer patients.
    Asian J Surg. 2024 Nov 29:S1015-9584(24)02515.
    PubMed    


  112. LIU B, Chen M, Liang Y, Mei Z, et al
    ZC3H13 promotes autophagy in bladder cancer through m6A methylation modification of PJA2 and ubiquitination of KSR1.
    Hum Cell. 2024;38:23.
    PubMed    
    Abstract available

  113. MYERS AA, Fang AM, Moussa MJ, Hwang H, et al
    Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder.
    ESMO Open. 2024;9:103964.
    PubMed    
    Abstract available

  114. DAN W, Fan Y, Wang Y, Hou T, et al
    The Tumor Suppressor TPD52-Governed Endoplasmic Reticulum Stress is Modulated by APC(Cdc20).
    Adv Sci (Weinh). 2024;11:e2405441.
    PubMed    
    Abstract available

  115. HUANG SY, Yu TS, Lin JH, Liu WH, et al
    Stable laminar shear stress induces G1 cell cycle arrest and autophagy in urothelial carcinoma by a torque sensor-coupled cone-and-plate device.
    Eur J Cell Biol. 2024;103:151451.
    PubMed    
    Abstract available

  116. WANG X, Zhang P, Yan J, Huang J, et al
    SIRT6 deficiency impairs the deacetylation and ubiquitination of UHRF1 to strengthen glycolysis and lactate secretion in bladder cancer.
    Cell Biosci. 2024;14:153.
    PubMed    
    Abstract available

  117. SEVKO A, Prevosto C, Ragavan S, Domingos-Pereira S, et al
    Immunomonitoring in bladder cancer: a short report on stability of leukocytes and proteins in refrigerated urine samples.
    BMC Urol. 2024;24:276.
    PubMed    
    Abstract available

  118. PICHLER R, Fritz J, Maier S, Hassler MR, et al
    Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer.
    Cancer Immunol Immunother. 2024;74:30.
    PubMed    
    Abstract available

  119. CHO M, Chang H, Kim JH
    Integration of bulk and single-cell RNA-seq reveals prognostic gene signatures in patients with bladder cancer treated with immune checkpoint inhibitors.
    Cancer Immunol Immunother. 2024;74:28.
    PubMed    
    Abstract available

  120. WU MH, Zhang MH, Hu XD, Fan HX, et al
    Proteome-wide Mendelian randomization and therapeutic targets for bladder cancer.
    BMC Urol. 2024;24:273.
    PubMed    
    Abstract available

  121. KHOSROBEIGI A, Sichani MM, Rangraz-Jeddi F, Gharakhani DD, et al
    A novel smartphone application for bladder cancer management (BCM App): Design, development, and usability evaluation.
    J Educ Health Promot. 2024;13:375.
    PubMed    
    Abstract available

  122. PARK SY
    Corrigendum to "Computed tomography-based prediction model for identifying patients with high probability of non-muscle-invasive bladder cancer" [Abdominal Radiology (2024) 49:163-172.].
    Abdom Radiol (NY). 2024 Dec 19. doi: 10.1007/s00261-024-04763.
    PubMed    


  123. LIU S, Feng C, Tan L, Zhang D, et al
    Single-cell dissection of multifocal bladder cancer reveals malignant and immune cells variation between primary and recurrent tumor lesions.
    Commun Biol. 2024;7:1659.
    PubMed    
    Abstract available

  124. HU X, Li G, Kong C, Liu L, et al
    Fluorinated chitosan mediated transepithelial delivery of sanguinarine-loaded platinum (IV) prodrug for intravesical instillation therapy of muscle-invasive bladder cancer.
    J Control Release. 2024 Dec 17:S0168-3659(24)00866.
    PubMed    
    Abstract available

  125. TASSINARI E, Danielli L, Marchetti A, Rosellini M, et al
    State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes.
    Hum Vaccin Immunother. 2025;21:2440165.
    PubMed    
    Abstract available

  126. EL SAFTAWY E, Aboulhoda BE, Alghamdi MA, Abd Elkhalek MA, et al
    Heterogeneity of modulatory immune microenvironment in bladder cancer.
    Tissue Cell. 2024;93:102679.
    PubMed    
    Abstract available

  127. NAKAGAWA R, Izumi K, Hiratsuka K, Inaba T, et al
    Tumor-associated macrophages promote bladder cancer metastasis through the CCL20-CCR6 axis.
    Neoplasia. 2024;60:101103.
    PubMed    
    Abstract available

  128. CANIZO CG, Guerrero-Ramos F, Perez Escavy M, Lodewijk I, et al
    Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer.
    Oncoimmunology. 2025;14:2438291.
    PubMed    
    Abstract available

  129. WANG YF, Li XG
    Application of cryoablation in animal models of bladder and muscle-invasive bladder cancer: a narrative review of current status and future perspectives.
    Quant Imaging Med Surg. 2024;14:9653-9666.
    PubMed    
    Abstract available

  130. SEO HK, Jung EH, Song G
    Exploring radiotherapy combined with a radiosensitizer for Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
    Transl Androl Urol. 2024;13:2354-2357.
    PubMed    


  131. GUO L, Chen N, Qiu M, Yang J, et al
    Immunogenic cell death-related signature predicts prognosis and immunotherapy efficacy in bladder cancer.
    Transl Cancer Res. 2024;13:5801-5814.
    PubMed    
    Abstract available

  132. SOLTANI-TEHRANI AM, Kumar A, Pohar KS
    Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.
    Transl Cancer Res. 2024;13:6489-6502.
    PubMed    
    Abstract available

  133. PATEL M, Moore K, Lichtbroun BL, Stephenson RD, et al
    Bladder sparing management for muscle-invasive bladder cancer after a complete clinical response: ready for prime time?-a narrative review.
    Transl Cancer Res. 2024;13:6413-6429.
    PubMed    
    Abstract available

  134. MORGAN D, Berggren KL, Millington G, Smith H, et al
    Loss of MK2 Enhances Radiation-Mediated Apoptosis in Bladder Cancer.
    World J Oncol. 2024;15:871-881.
    PubMed    
    Abstract available

  135. ZHAO J, Zhang Q, Zhu C, Yuqi W, et al
    Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs.
    BioData Min. 2024;17:59.
    PubMed    
    Abstract available

  136. ZHAO Y, Qiu W, Weng X, Gu C, et al
    ALK + anaplastic large cell lymphoma involving the bladder: case report and review of the literature.
    Diagn Pathol. 2024;19:157.
    PubMed    
    Abstract available

  137. TU CC, Hsieh TH, Chu CY, Lin YC, et al
    Targeting PPARgamma via SIAH1/2-mediated ubiquitin-proteasomal degradation as a new therapeutic approach in luminal-type bladder cancer.
    Cell Death Dis. 2024;15:908.
    PubMed    
    Abstract available

  138. TAYLOR J, Kamat AM, Annapureddy D, Khene ZE, et al
    Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guerin in Patients with Bacillus Calmette-Guerin-Unresponsive Non-Muscle Invasive Bladder Cancer.
    Eur Urol Oncol. 2024 Dec 17:S2588-9311(24)00288.
    PubMed    
    Abstract available

  139. LIEDBERG F, Xylinas E, Gontero P
    Reply to Laila Schneidewind, Fabian P. Stangl, Jennifer Kranz, and Gernot Bonkat's Letter to Editor re: Fredrik Liedberg, Evanguelos Xylinas, Paolo Gontero. Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations for Bladder C
    Eur Urol Focus. 2024 Dec 17:S2405-4569(24)00260.
    PubMed    


  140. SCILIPOTI P, Moschini M, Briganti A
    Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.
    Cell Rep Med. 2024;5:101873.
    PubMed    
    Abstract available

  141. ZHENG J, Zhang A, Du Q, Li C, et al
    Synergistic photoinduction of ferroptosis and apoptosis by a mitochondria-targeted iridium complex for bladder cancer therapy.
    J Colloid Interface Sci. 2024;683.
    PubMed    
    Abstract available

  142. ZHOU Z, Chai Y, Li Y, Zhang Y, et al
    Lipid metabolism subtypes reflects the prognosis and immune profiles of bladder cancer patients by NMF clustering and building related signature.
    Discov Oncol. 2024;15:796.
    PubMed    
    Abstract available

  143. PORSERUD A, Aly M, Steinertz H, Rydwik E, et al
    Exercise in primary care after robot-assisted radical cystectomy for urinary bladder cancer - effects on postoperative complications: a secondary analysis of a randomised controlled trial.
    Scand J Urol. 2024;59:193-199.
    PubMed    
    Abstract available

  144. ZHAO Z, Jia H, Sun Z, Li Y, et al
    A new perspective on macrophage-targeted drug research: the potential of KDELR2 in bladder cancer immunotherapy.
    Front Immunol. 2024;15:1485109.
    PubMed    
    Abstract available

  145. ZHAO T, He J, Zhang L, Li H, et al
    A multimodal deep-learning model based on multichannel CT radiomics for predicting pathological grade of bladder cancer.
    Abdom Radiol (NY). 2024 Dec 18. doi: 10.1007/s00261-024-04748.
    PubMed    
    Abstract available

  146. LIU K, Zhao H, Chen X, Wu H, et al
    Association Between Hypoglycemia Agents and Long-term Survival Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guerin Immunotherapy.
    Eur Urol Oncol. 2024 Dec 16:S2588-9311(24)00284.
    PubMed    
    Abstract available

  147. YING W, Zhao Y, He Y, Deng Y, et al
    Exosomal miR-184 facilitates bladder cancer progression by targeting AKR1C3 and inducing immune escape via IRF2-CXCL10 axis.
    Biochim Biophys Acta Mol Basis Dis. 2024;1871:167627.
    PubMed    
    Abstract available

  148. CHENG J, Wang L, Wang W, Liang H, et al
    HSPE1 Inhibits Bladder Cancer Ferroptosis via a Glutathione-Dependent Mechanism by Suppressing GPX4.
    Am J Mens Health. 2024;18:15579883241306904.
    PubMed    
    Abstract available

  149. PALETTA P, Mosconi P, Colombo C, Dossena E, et al
    [Not Available].
    Recenti Prog Med. 2024;115:630-631.
    PubMed    
    Abstract available

  150. HAN L, Yang H, Jiang X, Zhou Z, et al
    Prognostic model based on disulfidptosis-related lncRNAs for predicting survival and therapeutic response in bladder cancer.
    Front Immunol. 2024;15:1512203.
    PubMed    
    Abstract available

  151. NIE W, Jiang Y, Yao L, Zhu X, et al
    Prediction of bladder cancer prognosis and immune microenvironment assessment using machine learning and deep learning models.
    Heliyon. 2024;10:e39327.
    PubMed    
    Abstract available

  152. OLEYNIKOVA NA, Sycheva IN, Mikhailov IA, Zhestkov IA, et al
    [Patterns of CAF expression in tumors of the genitourinary system].
    Arkh Patol. 2024;86:28-35.
    PubMed    
    Abstract available

  153. HOU DY, You Q, Zhang P, Li XP, et al
    Cascade-Activatable Nanoprodrug System Augments Sonochemotherapy of Bladder Cancer.
    ACS Nano. 2024 Dec 17. doi: 10.1021/acsnano.4c12967.
    PubMed    
    Abstract available

  154. JASZEK N, Bogdanowicz A, Siwiec J, Starownik R, et al
    Epigenetic Biomarkers as a New Diagnostic Tool in Bladder Cancer-From Early Detection to Prognosis.
    J Clin Med. 2024;13:7159.
    PubMed    
    Abstract available

  155. KIM J, Ham WS, Koo KC, Lee J, et al
    Evaluation of the Diagnostic Efficacy of the AI-Based Software INF-M01 in Detecting Suspicious Areas of Bladder Cancer Using Cystoscopy Images.
    J Clin Med. 2024;13:7110.
    PubMed    
    Abstract available

  156. BACH-GRIERA M, Hernandez A, Julian E
    Mycobacteria Treatment Inhibits Bladder Cancer Cell Migration, Invasion, and Anchorage-Independent Growth.
    Int J Mol Sci. 2024;25:12997.
    PubMed    
    Abstract available

  157. MIKOLASKOVA I, Zvarik M, Szaboova K, Tibenska E, et al
    Association of Sympathovagal Imbalance with Increased Inflammation and Impaired Adaptive Immunity in Bladder Cancer Patients.
    Int J Mol Sci. 2024;25:12765.
    PubMed    
    Abstract available

  158. RUIZ-LORENTE I, Gimeno L, Lopez-Abad A, Lopez Cubillana P, et al
    Exploring the Immunoresponse in Bladder Cancer Immunotherapy.
    Cells. 2024;13:1937.
    PubMed    
    Abstract available

  159. YILDIRIM M
    Content-Based Image Retrieval and Image Classification System for Early Prediction of Bladder Cancer.
    Diagnostics (Basel). 2024;14:2637.
    PubMed    
    Abstract available

  160. PIGNOT G, Barthelemy P, Borchiellini D
    Sex Disparities in Bladder Cancer Diagnosis and Treatment.
    Cancers (Basel). 2024;16:4100.
    PubMed    
    Abstract available

  161. LIAO K, Li J, He C, Peng J, et al
    N6-methyladenosine-modified SRD5A3, identified by IGF2BP3, sustains cisplatin resistance in bladder cancer.
    Hum Cell. 2024;38:30.
    PubMed    
    Abstract available

  162. YANG Q, Yuan W, Zhao T, Jiao Y, et al
    Magnetic-Powered Spora Lygodii Microrobots Loaded with Doxorubicin for Active and Targeted Therapy of Bladder Cancer.
    Drug Des Devel Ther. 2024;18:5841-5851.
    PubMed    
    Abstract available

  163. AHANGAR M, Mahjoubi F, Mowla SJ
    Bladder cancer biomarkers: current approaches and future directions.
    Front Oncol. 2024;14:1453278.
    PubMed    
    Abstract available

  164. ZHANG Y, Peng L, Zhang Y, Li H, et al
    Clinical efficacy and safety of organ-sparing cystectomy: a systematic review and meta-analysis.
    PeerJ. 2024;12:e18427.
    PubMed    
    Abstract available

  165. GUO L, Zhao Y, Bai X, Wang X, et al
    RRM2 Is a Putative Biomarker and Promotes Bladder Cancer Progression via PI3K/AKT/mTOR Pathway.
    J Cell Physiol. 2024 Dec 16:e31501. doi: 10.1002/jcp.31501.
    PubMed    
    Abstract available

  166. AGRAWAL S, Kapoor V, Rahul R, Singh A, et al
    A Randomized Study of Consolidation Chemoradiation (CTRT) versus Observation after first line chemotherapy (CT) in Advanced Gall bladder Cancers (GBC):RACE-GB study.
    Int J Radiat Oncol Biol Phys. 2024 Dec 13:S0360-3016(24)03706.
    PubMed    
    Abstract available

  167. YANKELEVICH GR, Moreland K, Swancutt MM, Grubb RL, et al
    Illuminating the use of photodynamic therapy in urologic oncology.
    Can J Urol. 2024;31:12035-12044.
    PubMed    
    Abstract available

  168. SCHNEIDEWIND L, Stangl FP, Kranz J, Bonkat G, et al
    Re: Fredrik Liedberg, Evanguelos Xylinas, Paolo Gontero. Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box? Eur Urol Focus. In press. https:/
    Eur Urol Focus. 2024 Dec 13:S2405-4569(24)00258.
    PubMed    


  169. RAGGI D, Huddart RA
    Transformative or transitional? Deciphering the role of NIAGARA in shaping future practice.
    Med. 2024;5:1456-1458.
    PubMed    
    Abstract available

  170. MITTAL K, Joshi M
    Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward.
    Med. 2024;5:1449-1451.
    PubMed    
    Abstract available

  171. CHEN W, Wu S, Chen Y, Li W, et al
    USP20 mediates malignant phenotypic changes in bladder cancer through direct interactions with YAP1.
    Neoplasia. 2024;60:101102.
    PubMed    
    Abstract available

  172. JOHNSON AM, Johnson A, Hines RB, Zhu X, et al
    Racial differences in carcinoma-in-situ and non-muscle-invasive bladder cancer mortality: Accounting for insurance status, black segregation, and neighborhood poverty.
    Cancer Epidemiol. 2024;94:102728.
    PubMed    
    Abstract available

  173. DENG M, Zhou Z, Chen J, Li X, et al
    Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer.
    Adv Sci (Weinh). 2024 Dec 10:e2408599. doi: 10.1002/advs.202408599.
    PubMed    
    Abstract available

  174. YU A, Fu L, Jing L, Wang Y, et al
    Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.
    Cell Death Differ. 2024 Dec 13. doi: 10.1038/s41418-024-01434.
    PubMed    
    Abstract available

  175. CONTIERI R, Claps F, Hurle R, Buffi NM, et al
    Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy.
    Urol Oncol. 2024 Dec 12:S1078-1439(24)00748.
    PubMed    
    Abstract available

  176. CARBUNARU S, Neshatvar Y, Do H, Murray K, et al
    Survival After Radical Cystectomy for Bladder Cancer: Development of a Fair Machine Learning Model.
    JMIR Med Inform. 2024;12:e63289.
    PubMed    
    Abstract available

  177. WANG P, Jiang N, Zhong J, Chen Q, et al
    IFI27 enhances bladder cancer immunotherapy response by modulating regulatory T cell enrichment.
    J Cancer. 2024;15:6616-6630.
    PubMed    
    Abstract available

  178. YANG S, Jian J, Zhao X, Wang L, et al
    Causal Association of Adipose Tissue with Bladder Cancer and the Mediating Effects of Circulating Metabolites: A Mendelian Randomization Study.
    J Cancer. 2024;15:6521-6530.
    PubMed    
    Abstract available

  179. GORBOKON N, Wossner N, Ahlburg V, Plage H, et al
    Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer.
    J Pathol Clin Res. 2025;11:e70012.
    PubMed    
    Abstract available

  180. APOSTOLSKI D, Roitner F
    Gastric Outlet Obstruction as a First Symptom of a Non-Muscle Invasive Bladder Cancer (NMIBC) Progression-A Case Report.
    Cancer Rep (Hoboken). 2024;7:e70077.
    PubMed    
    Abstract available

  181. ZHU L, Xiao F, Hou Y, Huang S, et al
    Identification of anoikis-related molecular patterns and the novel risk model to predict prognosis, tumor microenvironment infiltration and immunotherapy response in bladder cancer.
    Front Immunol. 2024;15:1491808.
    PubMed    
    Abstract available

  182. ZHUANG J, Zhou M, Yu H, Zhou R, et al
    CircFAM64A(3) promoted bladder cancer proliferation and inhibited CD8 + T cell via sponging to miR-149-5p and activated IL-6/JAK/STAT pathway.
    Int Immunopharmacol. 2025;145:113762.
    PubMed    
    Abstract available

  183. MOODY KA, Iofel SS, Clements MB
    Health-Related Quality of Life Across the Spectrum of Bladder Cancer: A Current Review.
    Curr Urol Rep. 2024;26:21.
    PubMed    
    Abstract available

  184. WU Y, Meng Z, Bao Y, Zhao X, et al
    Association between family functioning and delay in seeking medical care of Chinese bladder cancer patients: the mediating effect of coping styles.
    Support Care Cancer. 2024;33:15.
    PubMed    
    Abstract available

  185. ZHANG ZR, Liu MQ, Ji Y, Xiao D, et al
    Sotorasib inhibits ubiquitination degradation of TXNIP and suppresses glucose metabolism in KRAS(G12C) mutant bladder cancer.
    Am J Cancer Res. 2024;14:5251-5268.
    PubMed    
    Abstract available

  186. XIANG Y, Wen Z, Yang M, Lyu H, et al
    Case report: A rare case of renal tuberculosis combined with bladder cancer.
    Front Oncol. 2024;14:1423744.
    PubMed    
    Abstract available

  187. WU X, Sheng X
    Molecular subtyping in urothelial carcinoma treatment.
    Cancer Cell. 2024;42:1993-1996.
    PubMed    
    Abstract available

  188. EOM KY, Mann B, Halpern MT
    Integrated care among patients with kidney or urinary bladder cancer: An NCI patterns-of-care analysis.
    Urol Oncol. 2024 Dec 9:S1078-1439(24)00745-2. doi: 10.1016/j.urolonc.2024.
    PubMed    
    Abstract available

  189. YAO D, Yu W, Ma X, Tian J, et al
    A novel necroptosis-related genes signature to predict prognosis and treatment response in bladder cancer.
    Front Mol Biosci. 2024;11:1493411.
    PubMed    
    Abstract available

  190. HARADA GK, Seyedin SN, Heutlinger O, Azizi A, et al
    A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy.
    Adv Radiat Oncol. 2024;10:101671.
    PubMed    
    Abstract available

  191. JIA Y, Wu K, Li X
    Association between tumor size and prognosis in bladder cancer: novel classifications and insights from a SEER database analysis.
    Front Surg. 2024;11:1489832.
    PubMed    
    Abstract available

  192. TRUONG A, Liu J, Ni C, Yashar S, et al
    Chilblain lupus erythematosus associated with erdafitinib therapy in a patient with metastatic bladder cancer.
    JAAD Case Rep. 2024;54:62-65.
    PubMed    


  193. HU W, Zhou Z, Zou F, Huang Y, et al
    Harnessing Natural Pollen as Sustained-Release, Mucoadhesive, and Biosafe Drug Microcapsules for Intravesical Instillation in Bladder Cancer Treatment.
    Small. 2024 Dec 9:e2406351. doi: 10.1002/smll.202406351.
    PubMed    
    Abstract available

  194. LV Y, Song B, Yang G, Wang Y, et al
    In Situ Transformable Nanoparticle Effectively Suppresses Bladder Cancer by Damaging Mitochondria and Blocking Mitochondrial Autophagy Flux.
    Adv Sci (Weinh). 2024 Dec 9:e2409425. doi: 10.1002/advs.202409425.
    PubMed    
    Abstract available

  195. LIU Z, Pu X
    Orosomucoid 1 interacts with S100A12 and activates ERK signalling to expedite the advancement of bladder cancer.
    Cell Adh Migr. 2025;19:1-11.
    PubMed    
    Abstract available

  196. WANG JF, Wang JS, Liu Y, Ji B, et al
    Knockdown of integrin beta1 inhibits proliferation and promotes apoptosis in bladder cancer cells.
    Biofactors. 2024 Dec 7. doi: 10.1002/biof.2150.
    PubMed    
    Abstract available

  197. CAO Z, Yan R, Chen J, She M, et al
    Water-Soluble Fluorescent Sensors for Quantification of Trace Cisplatin in Body Fluids from Clinical Cancer Patients.
    J Am Chem Soc. 2024;146:33651-33662.
    PubMed    
    Abstract available

  198. HAMIDI H, Senbabaoglu Y, Beig N, Roels J, et al
    Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
    Cancer Cell. 2024;42:2098-2112.
    PubMed    
    Abstract available

  199. ROHENA-RIVERA K, You S, Kim M, Billet S, et al
    Targeting ketone body metabolism in mitigating gemcitabine resistance.
    JCI Insight. 2024;9:e177840.
    PubMed    
    Abstract available

  200. TIAN Y, Ren C, Shi L, Guo Z, et al
    Surgical treatment of urachal adenocarcinoma with lung metastasis: A case report and literature review.
    Thorac Cancer. 2024;15:2509-2513.
    PubMed    
    Abstract available

  201. KAVAS G, Celik B
    Reclassification of Urinary Cytology according to the Paris System for Reporting Urinary Cytology Correlation with Histological Diagnosis.
    Acta Cytol. 2024;68:544-554.
    PubMed    
    Abstract available

  202. DI BELLO F, Siech C, de Angelis M, Rodriguez Penaranda N, et al
    Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients.
    Ann Surg Oncol. 2025;32:583-588.
    PubMed    
    Abstract available

  203. BREAU RH, Lavallee LT, Cagiannos I, Momoli F, et al
    Tranexamic Acid During Radical Cystectomy: A Randomized Clinical Trial.
    JAMA Surg. 2024;159:1355-1363.
    PubMed    
    Abstract available

  204. SAMARA M, Thodou E, Apostolopoulou C, Vlachostergios PJ, et al
    Evaluation of a Cytology-Molecular Co-Test in Liquid-Based Cytology-Processed Urine for Defining Indeterminate Categories of the Paris System.
    Acta Cytol. 2024;68:532-543.
    PubMed    
    Abstract available

  205. PARK K, Kim EJ, Kim JY, Kim H, et al
    Four versus six cycles of platinum-based chemotherapy for advanced Urothelial carcinoma in the era of immune checkpoint inhibitors: A retrospective cohort study (FOCUS, KCSG-GU23-08).
    Curr Probl Cancer. 2024;53:101149.
    PubMed    
    Abstract available

  206. SINGH A, Khan AA, Ahluwalia C, Ahuja S, et al
    Diagnostic Accuracy of the Second Edition of the Paris System for Reporting High-Grade Urothelial Carcinoma in Urinary Cytology.
    Acta Cytol. 2024;68:525-531.
    PubMed    
    Abstract available

  207. SHAH MS, Hochberg AR, Prebay ZJ, Shah YB, et al
    Stent vs Stentless Ileal Conduits After Radical Cystectomy: Is There a Difference in Early Postoperative Outcomes?
    Urol Pract. 2025;12:139-146.
    PubMed    
    Abstract available

  208. COEN JJ, Rodgers JP, Saylor PJ, Lee CT, et al
    Long-Term Results of Bladder Preservation With Twice-Daily Radiation Plus 5-Fluorouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer-Updated Report of NRG/RTOG 0712: A Randomized Phase 2 Trial.
    Int J Radiat Oncol Biol Phys. 2025;121:153-161.
    PubMed    
    Abstract available

  209. CHANG SJ, Chen WT, Chai CY
    Arsenic-induced disruption of circadian rhythms and glutamine anaplerosis in human urothelial carcinoma.
    J Trace Elem Med Biol. 2024;86:127507.
    PubMed    
    Abstract available

  210. JEONG HJ, Kang YJ, Choo MS, Jeong SJ, et al
    Excluding confusable diseases in patients with presumptive diagnosis of interstitial cystitis: A large patient cohort study.
    Int J Gynaecol Obstet. 2025;168:369-376.
    PubMed    
    Abstract available

  211. NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
    Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma.
    Jpn J Clin Oncol. 2024;54:1329-1335.
    PubMed    
    Abstract available

  212. HAFEEZ S, Warren-Oseni K, Jones K, Mohammed K, et al
    Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study.
    Int J Radiat Oncol Biol Phys. 2025;121:165-175.
    PubMed    
    Abstract available

  213. WONG CH, Ko IC, Leung DK, Yuen SK, et al
    Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC).
    Eur Urol Oncol. 2024;7:1171-1174.
    PubMed    
    Abstract available

  214. SUBIELA JD, Krajewski W, Gonzalez-Padilla DA, Laszkiewicz J, et al
    Unlocking the Potential of Adequate Bacillus Calmette-Guerin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics.
    Eur Urol Oncol. 2024;7:1367-1375.
    PubMed    
    Abstract available

  215. LEE YT, Chen CC, Chao H, Chang CC, et al
    Planned Abscopal Effect with Concurrent Pembrolizumab and Ablative Radiotherapy to Pulmonary Metastasis: A Case Report and Review of the Literature.
    Curr Oncol. 2024;31:7787-7792.
    PubMed    
    Abstract available

  216. BAZZI N, Jaber S, Saad WA, Al Hassan S, et al
    Cutaneous Metastasis of Bladder Cancer: A Systematic Review.
    Cureus. 2024;16:e74439.
    PubMed    
    Abstract available

  217. YU Z, Tan G, Yu C, Chen Y, et al
    Targeting LncRNA ADAMTS9-AS1 is a Promising Therapeutic Strategy to Inhibit the Progression of Bladder Cancer.
    Discov Med. 2024;36:2454-2464.
    PubMed    
    Abstract available

  218. NOUH MR, Ezz Eldin O
    Precise vesical wall staging of bladder cancer in the era of precision medicine: has it been fulfilled?
    Abdom Radiol (NY). 2024 Dec 27. doi: 10.1007/s00261-024-04786.
    PubMed    
    Abstract available

  219. TING HK, Dou YC, Lin YH, Chen TM, et al
    Pyr3 inhibits cell viability and PKCalpha activity to suppress migration in human bladder cancer cells.
    Eur J Pharmacol. 2024 Dec 24:177235. doi: 10.1016/j.ejphar.2024.177235.
    PubMed    
    Abstract available

  220. FINATI M, Fanelli A, Cinelli F, Schiavone N, et al
    Oncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series.
    World J Urol. 2024;43:47.
    PubMed    
    Abstract available

  221. TSENG WH, Chiang TY, Ho CH, Huang SK, et al
    Navigating the obesity paradox in bladder cancer prognosis-insights from the Taiwan National Health Insurance System Database.
    Front Nutr. 2024;11:1433632.
    PubMed    
    Abstract available

  222. NAGUIB EM, Ismail EF, Badran DI, Sherief MH, et al
    Clinicopathological significance of c-MET and HER2 altered expression in bladder cancer.
    J Egypt Natl Canc Inst. 2024;36:42.
    PubMed    
    Abstract available

  223. CAO Y, Wang S, Ma J, Long M, et al
    Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells.
    Cell Death Dis. 2024;15:931.
    PubMed    
    Abstract available

  224. BEIGREZAEI S, Dianati M, Salehi-Abargouei A, Fararouei M, et al
    The association between animal protein, plant protein, and their substitution with bladder cancer risk: a pooled analysis of 10 cohort studies.
    Eur J Nutr. 2024;64:55.
    PubMed    
    Abstract available

  225. BREMBILLA G, Basile G, Cosenza M, Giganti F, et al
    Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI.
    Radiology. 2024;313:e233020.
    PubMed    
    Abstract available

  226. WANG Y, Zhu J, Liu S, Sun Z, et al
    CRISPR-Cas13a Targeting the FGFR3-TACC3 Fusion Gene Inhibits Proliferation of Bladder Cancer Cells in vitro and in vivo.
    Onco Targets Ther. 2024;17:1197-1207.
    PubMed    
    Abstract available

  227. LEMBERGER U, Ernhofer B, Krieger S, Bruchbacher A, et al
    Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol Open Sci. 2024;71:38-48.
    PubMed    
    Abstract available

  228. REN S, Lu Y, Zhang G, Xie K, et al
    Integration of Graph Neural Networks and multi-omics analysis identify the predictive factor and key gene for immunotherapy response and prognosis of bladder cancer.
    J Transl Med. 2024;22:1141.
    PubMed    
    Abstract available

  229. RABIEN A, Rong D, Rabenhorst S, Schlomm T, et al
    Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer.
    Sci Rep. 2024;14:30617.
    PubMed    
    Abstract available

  230. ZHAO X, Qi X, Liu D, Che X, et al
    A Novel Approach for Bladder Cancer Treatment: Nanoparticles as a Drug Delivery System.
    Int J Nanomedicine. 2024;19:13461-13483.
    PubMed    
    Abstract available

  231. HUANG Y, Xu M, Ma X, Wang W, et al
    Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess.
    Front Pharmacol. 2024;15:1503154.
    PubMed    
    Abstract available

  232. ZHANG J, He J, Qiang Z, Zhang J, et al
    Methyltransferase like 13 promotes malignant behaviors of bladder cancer cells through targeting PI3K/ATK signaling pathway.
    Open Life Sci. 2024;19:20220981.
    PubMed    
    Abstract available

  233. LI J, Jiang Y, Ma M, Wang L, et al
    IGF2BP2 Shapes the Tumor Microenvironment by Regulating Monocyte and Macrophage Recruitment in Bladder Cancer.
    Cancer Med. 2024;13:e70506.
    PubMed    
    Abstract available

  234. HONDA H, Matsuo T, Mori S, Araki K, et al
    [Risk Factor of Cutaneous Symptoms Associated with Enfortumab Vedotin for Urothelial Carcinoma].
    Hinyokika Kiyo. 2024;70:361-366.
    PubMed    
    Abstract available

  235. KOTHA NV, Kumar A, Riviere P, Nelson TJ, et al
    Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2024;23:102229.
    PubMed    
    Abstract available

  236. MINATO A, Yoshii M, Watanabe S, Moriya R, et al
    Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer.
    Jpn J Clin Oncol. 2024 Dec 22:hyae183. doi: 10.1093.
    PubMed    
    Abstract available

  237. YU X, Wang C, Wang L, Pang Y, et al
    Impact of ERAS on Hysteromyomectomy: A Study on Anxiety, Depression, and Ovarian Function.
    Altern Ther Health Med. 2024;30:249-255.
    PubMed    
    Abstract available

  238. JARADAT JH, Idrissi YA, Saeed A
    HOOK3 Amplification in Bladder Urothelial Carcinoma: Insights from Gene Expression and Survival Analysis.
    Anticancer Res. 2024;44:5175-5185.
    PubMed    
    Abstract available

  239. GUO AA, Zeng K, Bushati Y, Kim P, et al
    Cardiopulmonary exercise testing prior to radical cystectomy: a systematic review and meta-analysis.
    BJU Int. 2024;134 Suppl 2:22-29.
    PubMed    
    Abstract available

  240. AKDEMIR E, Stuiver MM, van de Kamp MW, der Hulst JB, et al
    Long-term quality of life in patients with bladder cancer following radical cystectomy.
    BJU Int. 2024 Dec 1. doi: 10.1111/bju.16610.
    PubMed    
    Abstract available

  241. LONGONI M, Di Bello F, Rodriguez Penaranda N, Falkenbach F, et al
    Survival after trimodal therapy in octogenarians with organ-confined urothelial bladder cancer.
    BJU Int. 2024 Dec 12. doi: 10.1111/bju.16622.
    PubMed    
    Abstract available

  242. HAILE ES, Lone Z, Shin D, Nowacki AS, et al
    Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function.
    BJU Int. 2024 Dec 9. doi: 10.1111/bju.16606.
    PubMed    
    Abstract available

  243. PFAIL J, Capellan J, Passarelli R, Kaldany A, et al
    National Surgical Quality Improvement Program audit of contemporary perioperative care for radical cystectomy.
    BJU Int. 2025;135:140-147.
    PubMed    
    Abstract available

  244. JOHN JB, Collins M, Eames S, O'Flynn K, et al
    The carbon footprint of the perioperative transurethral resection of bladder tumour pathway.
    BJU Int. 2025;135:78-87.
    PubMed    
    Abstract available

  245. BERGEROT CD, Schmitz KH, Crane TE, Klaassen Z, et al
    Comprehensive care for patients with bladder cancer: Addressing the interplay of physical, nutritional, and emotional well-being.
    Cancer. 2024 Nov 28. doi: 10.1002/cncr.35670.
    PubMed    


  246. PRABAGAR MG, McQueney M, Bommireddy V, Siegel R, et al
    THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER.
    Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-1022.
    PubMed    
    Abstract available

  247. FLECHON A, Morales-Barrera R, Powles T, Alva A, et al
    Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.
    Clin Cancer Res. 2024;30:5353-5364.
    PubMed    
    Abstract available

  248. COLBERT L, Jia Y, Sharma A, Hu J, et al
    FDA Approval Summary: Nadofaragene firadenovec-vncg for bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
    Clin Cancer Res. 2024 Dec 20. doi: 10.1158/1078-0432.CCR-24-2812.
    PubMed    
    Abstract available

  249. AFFERI L, Cimadamore A, Gallioli A, Pradere B, et al
    Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
    Eur Urol. 2025;87:1-4.
    PubMed    
    Abstract available

  250. PALERMO G, Bizzarri FP, Scarciglia E, Sacco E, et al
    The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score-matched study.
    Int J Urol. 2024;31:1423-1428.
    PubMed    
    Abstract available

  251. SASAKI Y, Fukuta K, Kadoriku F, Daizumoto K, et al
    Retroperitoneal cutaneous ureterostomy following radical cystectomy: A multicenter comparative study of robotic versus open surgery.
    Int J Urol. 2024;31:1408-1413.
    PubMed    
    Abstract available

  252. MORIZANE S, Miki J, Shimbo M, Kanno T, et al
    Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
    Int J Urol. 2024;31:1300-1310.
    PubMed    
    Abstract available

  253. TAOKA R, Fujimoto K, Inoue K, Tsuzuki T, et al
    Accuracy of photodynamic diagnosis for non-muscle-invasive bladder cancer: Exploratory analysis of anatomical locations and tumor types using data from a prospective, single-arm, multicenter phase III trial.
    Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15653.
    PubMed    


  254. NAKAMURA Y, Yoshida S, Arita Y, Takeshita R, et al
    The need for a second transurethral resection in high-risk non-muscle-invasive bladder cancer based on the Vesicle Imaging-Reporting and Data System.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15638.
    PubMed    
    Abstract available

  255. IVANIC D, Dug H, Jagodic S, Delibegovic S, et al
    Preoperative neutrophil-to-lymphocyte ratio (NLR) value as a predictor of recurrence of non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2024 Nov 27. doi: 10.1007/s11255-024-04297.
    PubMed    
    Abstract available

  256. SEVEN I, Akturk Esen S, Sekmek S, Karahan I, et al
    Clinicopathological features and treatment outcomes of urothelial carcinoma variant histologies and non-urothelial bladder cancers.
    Int Urol Nephrol. 2024 Dec 27. doi: 10.1007/s11255-024-04341.
    PubMed    
    Abstract available

  257. GEYNISMAN DM, Abbosh PH, Ross E, Zibelman MR, et al
    Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
    J Clin Oncol. 2024 Dec 16:JCO2401214. doi: 10.1200/JCO-24-01214.
    PubMed    
    Abstract available

  258. GALSKY MD, Witjes JA, Gschwend JE, Milowsky MI, et al
    Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
    J Clin Oncol. 2025;43:15-21.
    PubMed    
    Abstract available

  259. CHEN H, Wu M, Chen M
    Evaluation of the Management of Urachal Carcinoma: A Single-Center Experience over 13 Years.
    Urol Int. 2024;108:508-516.
    PubMed    
    Abstract available

  260. TULLY K, Bahlburg H, Reike MJ, Brehmer M, et al
    Discrimination of T-stage using tumor weight and size - a potential approach to guide perioperative decision making in patients with bladder cancer.
    Urol Int. 2024 Dec 16:1-15. doi: 10.1159/000543112.
    PubMed    
    Abstract available

  261. LIU H, Jin L, Shi J
    Incidence and risk factors for postoperative acute kidney injury after radical cystectomy for bladder cancer.
    Urology. 2024 Nov 25:S0090-4295(24)01092-6. doi: 10.1016/j.urology.2024.
    PubMed    


  262. ECKE TH, Meisl CJ, Schlomm T, Rabien A, et al
    Performance of urinary markers in patients with suspicious cystoscopy during follow-up of recurrent non-muscle invasive bladder cancer: BTA stat(R), NMP22(R) BladderChek(R), UBC(R) Rapid Test, CancerCheck(R) UBC(R) rapid VISUAL, and uromonitor(R) in c
    Urology. 2024 Dec 1:S0090-4295(24)01113-0. doi: 10.1016/j.urology.2024.
    PubMed    
    Abstract available

  263. ZENG E, Saucke M, Pati B, Rose A, et al
    "...I Wish Someone Told Me About That...": A Qualitative Assessment of the Educational Needs of Patients Undergoing Cystectomy.
    Urology. 2024;194:348-355.
    PubMed    
    Abstract available

  264. MEKAYTEN M, Tin AL, Sidhu A, Liso N, et al
    Trans Oblique Ileal Conduit Technique Has a Low Risk of Parastomal Hernias.
    Urology. 2024;194:241-246.
    PubMed    
    Abstract available

  265. SCHUCK S, Loussikian P, Mebarki A, Malaab J, et al
    Perceived unmet needs and impact on quality of life of patients living with advanced bladder cancer and their caregivers: results of a social media listening study conducted in five European countries.
    BMC Cancer. 2024;24:1444.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;